Tengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.

Video: Tengion Neo-Bladder™ Construction

Tengion is developing products that seek to transform the treatment of organ and tissue impairment, failure and loss.

* Internet Explorer users only:
You may be redirected to upgrade security components and install an Active X control.

The video you are linking to depicts experimental technology invented by, and procedures performed at, Children's Hospital Boston. This technology serves as the foundation for Tengion's lead product candidate, the Neo-Bladder Augment, which is currently in Phase II clinical trials. Tengion's Neo-Bladder Augment is investigational and has not been approved by the FDA for commercial sale. Additionally, the Neo-Bladder Augment may not be appropriate for all patients and medical results depicted in this video may not be experienced by others using this technology.

Message from our President and Chief Executive Officer

Steven Nichtberger, M.D.

This is the reason we get to work early every morning - there's a death every thirty seconds from organ failure. As I write this letter, there are 99,832 Americans on the waiting list for donor organs, and if they are fortunate enough to find one, they will face a lifetime of treatment to suppress their immune systems to prevent rejection. Read More »

Tengion Announces Expanded European Orphan Medicinal Product Designation for Neo-Bladder Augment

September 22, 2008

Tengion Appoints Brian J. G. Pereira, M.D. to its Board of Directors

September 22, 2008

Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association

September 19, 2008

Tengion Scientists Publish Positive Preclinical Findings with Neo-Organ Demonstrating Long-term Durability and Growth with Skeletal Maturation

September 18, 2008